These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 24603082)

  • 1. Pharmaceutical policy reform in the Russian Federation.
    Rudisill C; Vandoros S; Antoun JG
    J Health Polit Policy Law; 2014 Jun; 39(3):691-705. PubMed ID: 24603082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
    Mansfield SJ
    Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmaceutical policy in China.
    Sun Q; Santoro MA; Meng Q; Liu C; Eggleston K
    Health Aff (Millwood); 2008; 27(4):1042-50. PubMed ID: 18607039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Australian pharmaceutical policy: price control, equity, and drug innovation in Australia.
    Doran E; Alexander Henry D
    J Public Health Policy; 2008 Apr; 29(1):106-20. PubMed ID: 18368023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [International reference prices and cost minimization analysis for the regulation of medicine prices in Colombia].
    Vacca C; Acosta A; Rodriguez I
    Value Health; 2011; 14(5 Suppl 1):S16-9. PubMed ID: 21839891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [An analysis of the pharmaceuticals market in Vietnam].
    Simonet D
    Sante; 2001; 11(3):155-60. PubMed ID: 11641078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural changes in the German pharmaceutical market: price setting mechanisms based on the early benefit evaluation.
    Henschke C; Sundmacher L; Busse R
    Health Policy; 2013 Mar; 109(3):263-9. PubMed ID: 23339876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generic medicine pricing in Europe: current issues and future perspective.
    Simoens S
    J Med Econ; 2008; 11(1):171-5. PubMed ID: 19450118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value-based differential pricing: efficient prices for drugs in a global context.
    Danzon P; Towse A; Mestre-Ferrandiz J
    Health Econ; 2015 Mar; 24(3):294-301. PubMed ID: 24327269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High prices for generics in Australia - more competition might help.
    Bulfone L
    Aust Health Rev; 2009 May; 33(2):200-14. PubMed ID: 19563309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Balancing health and industrial policy objectives in the pharmaceutical sector: lessons from Australia.
    Morgan S; McMahon M; Greyson D
    Health Policy; 2008 Aug; 87(2):133-45. PubMed ID: 18295927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of generic competition on the price of brand-name drugs.
    Lexchin J
    Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Mechanics and effects of European reference pricing for vaccines in Germany according to §130a Abs. 2 SGB V: an analysis using the example of influenza vaccines].
    Barth J; Hammerschmidt T; Vollmar J; Bierbaum M; Schöffski O
    Gesundheitswesen; 2014 Apr; 76(4):e7-e13. PubMed ID: 24081570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
    Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
    Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of Spanish generic medicines retail market: recommendations to enhance long-term sustainability.
    Dylst P; Vulto AG; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2014 Jun; 14(3):345-53. PubMed ID: 24758569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential pricing of new pharmaceuticals in lower income European countries.
    Kaló Z; Annemans L; Garrison LP
    Expert Rev Pharmacoecon Outcomes Res; 2013 Dec; 13(6):735-41. PubMed ID: 24219049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Competition in the off-patent medicine market in Spain: The national reference pricing system versus the regional system of tendering for outpatient prescription medicines in Andalusia.
    Casanova-Juanes J; Mestre-Ferrandiz J; Espín-Balbino J
    Health Policy; 2018 Dec; 122(12):1310-1315. PubMed ID: 30389186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Future European health care: cost containment, health care reform and scientific progress in drug research.
    Emilien G
    Int J Health Plann Manage; 1997; 12(2):81-101. PubMed ID: 10173136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controlling medicine prices in Sudan: the challenge of the recently established medicines regulatory authority.
    Ali GK; Yahia Y
    East Mediterr Health J; 2012 Aug; 18(8):811-20. PubMed ID: 23057369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.